Compare AMBO & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMBO | BCAB |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5M | 6.4M |
| IPO Year | 2010 | 2020 |
| Metric | AMBO | BCAB |
|---|---|---|
| Price | $2.38 | $3.56 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 51.4K | 35.1K |
| Earning Date | 08-05-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 337.04 | 29.86 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $9,469,000.00 | $300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $290.54 | ★ N/A |
| Revenue Growth | ★ 0.82 | N/A |
| 52 Week Low | $1.47 | $0.12 |
| 52 Week High | $6.75 | $6.52 |
| Indicator | AMBO | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 40.65 | 49.11 |
| Support Level | $1.91 | $3.19 |
| Resistance Level | $2.56 | $5.18 |
| Average True Range (ATR) | 0.24 | 0.33 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 12.12 | 61.49 |
Ambow Education Holding Ltd is an AI-driven technology educational company. Along with its subsidiaries, the company is developing a new HybriU AI Digital Education Solution that transforms the educational environment, bridging the gap between traditional methods and the future of digital learning. The solution combines sophisticated software and hardware to create an AI-powered digital and hybrid classroom, designed to enhance educational delivery and engagement. In addition, the group offers high-quality, individualized, and dynamic career education services and products through the operation of its for-profit colleges. Substantially the majority of the group's revenues are derived from the United States, based on the geographical locations where services are provided to customers.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.